Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 3/20 | 0.58 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | F7 | P08709 | 3/20 | 0.44 |
| ▸ | F3 | P13726 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099047 | 1.00 | GRIK1 (0.58) | GRIK1GRIK2ALDH1A1CYP19A1MAPT | |
| SCHEMBL3824913 | 1.00 | GRIK1 (0.58) | GRIK1GRIK2ALDH1A1CYP19A1MAPT | |
| SCHEMBL2754220 | 1.00 | GRIK1 (0.58) | GRIK1GRIK2ALDH1A1CYP19A1MAPT | |
| SCHEMBL2754221 | 1.00 | GRIK1 (0.58) | GRIK1GRIK2ALDH1A1CYP19A1MAPT | |
| SCHEMBL3824909 | 1.00 | GRIK1 (0.58) | GRIK1GRIK2ALDH1A1CYP19A1MAPT | |
| SCHEMBL2754222 | 1.00 | GRIK1 (0.58) | GRIK1GRIK2ALDH1A1CYP19A1MAPT | |
| SCHEMBL3215984 | 0.94 | GRIK1 (0.53) | GRIK1GRIK2ALDH1A1CYP19A1MAPT | |
| SCHEMBL3215976 | 0.94 | GRIK1 (0.53) | GRIK1GRIK2ALDH1A1CYP19A1MAPT | |
| SCHEMBL9306152 | 0.94 | GRIK1 (0.63) | GRIK1GRIK2ALDH1A1CYP19A1MAPT | |
| SCHEMBL5494285 | 0.94 | GRIK1 (0.63) | GRIK1GRIK2ALDH1A1CYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2010508262-A | — | — | 2010-03-18 | — | — | JP | claimed |
| EP-2102139-A2 | OMEGA-3 LIPID COMPOUNDS | Pronova Biopharma Norge AS (NO) | 2009-09-23 | — | — | EP | claimed |
| US-20080300306-A1 | Novel Compounds | BRYHN MORTEN | 2008-12-04 | — | — | US | claimed |
| WO-2008142482-A2 | OMEGA-3 LIPID COMPOUNDS | PRONOVA BIOPHARMA NORGE AS (US) | 2008-11-27 | — | — | WO | claimed |
| EP-3383380-B1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2023-01-04 | — | — | EP | disclosed |
| US-20190284129-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2019-09-19 | — | — | US | disclosed |
| WO-2017093732-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2017-06-08 | — | — | WO | disclosed |
| US-8034842-B2 | Compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-10-11 | — | — | US | disclosed |
| US-20110166228-A1 | COMPOSITION | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-07-07 | — | — | US | disclosed |
| US-20100267828-A1 | DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-10-21 | — | — | US | disclosed |
| US-20100267828-A1 | DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-10-21 | — | — | US | disclosed |
| EP-2102139-A2 | OMEGA-3 LIPID COMPOUNDS | Pronova Biopharma Norge AS (NO) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009056983-A1 | NEW DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS | PRONOVA BIOPHARMA NORGE AS (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20080300306-A1 | Novel Compounds | BRYHN MORTEN | 2008-12-04 | — | — | US | disclosed |
| WO-2008142482-A2 | OMEGA-3 LIPID COMPOUNDS | PRONOVA BIOPHARMA NORGE AS (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008053340-A1 | A COMBINATION PRODUCT COMPRISING AT LEAST ONE LIPID SUBSTITUTED IN THE ALPHA POSITION AND AT LEAST ONE HYPOGLYCEMIC AGENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166228-A1 | COMPOSITION | ELOVL3, FFAR3, ALOX5 | GRIK1 1219/4885GRIK2 918/4885ALDH1A1 1710/4885 |
| US-20190284129-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | APOB, ALOX12, NR1H2 | GRIK1 530/4885GRIK2 801/4885ALDH1A1 417/4885 |
| US-20100267828-A1 | DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS | LIPA, LPL, PNLIP | GRIK1 2924/4885GRIK2 3151/4885ALDH1A1 1114/4885 |
| US-20080300306-A1 | Novel Compounds | GPR119, FFAR2, ALOX12 | GRIK1 2174/4885GRIK2 1389/4885ALDH1A1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.